Medication info
Dapaen Duo Extended-Release Tablet 10/1000 mg

Dapaen Duo Extended-Release Tablet 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin citric acid›14.7mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
HK Inno.N Co., Ltd.
Appearance
Yellow, film-coated egg-shaped tablet with a biconvex surface on both sides
Packaging
30 tablets / bottle
Approval status
Active

MFDS item code 202106824 · Approved 2021.10.08 · Insurance code 640007810

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions to metformin. For patients being treated with metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the same or a therapeutically appropriate dose close to the metformin dose the patient was taking. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering drug. Because changes may result in altered blood glucose control, any change in treatment in patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Metformin is excreted through the kidneys, and renal function is more likely to decline in elderly patients; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Ingredients

Manufacturer
HK Inno.N Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood sugar control issues
  • cardiovascular diseases
  • cardiovascular risk factors
View approved original text

This medication is used to help control blood sugar in adults with type 2 diabetes who are taking dapagliflozin and metformin in combination. It is prescribed as an adjunct to diet and exercise to effectively lower blood sugar levels. Additionally, for patients with type 2 diabetes who do not achieve adequate blood sugar control and have cardiovascular disease or risk factors, the impact of dapagliflozin on the occurrence of cardiovascular events should be referred to expert guidance. This medication is used to treat with consideration of both blood sugar management and cardiovascular health.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions to metformin. For patients being treated with metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the same or a therapeutically appropriate dose close to the metformin dose the patient was taking. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering drug. Because changes may result in altered blood glucose control, any change in treatment in patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Metformin is excreted through the kidneys, and renal function is more likely to decline in elderly patients; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Precautions

This medication is used for the treatment of diabetes. This medication should not be used in patients with impaired kidney function or in conditions that can affect kidney function such as dehydration, severe infections, or acute myocardial infarction. Additionally, it is safer not to administer it to pregnant or nursing women. This medication can occasionally cause a rare side effect called lactic acidosis, so patients should consult a doctor immediately if symptoms such as fatigue, muscle pain, difficulty breathing, or abdominal pain occur. When used in combination with other diabetes medications, there is a risk of hypoglycemia, so insulin or sulfonylurea dosage adjustments may be necessary. During treatment with this medication, regular monitoring of kidney function, blood pressure, and electrolyte status is required to ensure there are no abnormalities. Furthermore, patients who are dehydrated or have low blood pressure should be especially cautious, and any signs of dehydration should be treated immediately. This medication can increase the risk of genital and urinary tract infections, so rapid treatment is necessary if there are any signs of infection. Vitamin B12 deficiency can occur, so it’s advisable to monitor blood vitamin B12 levels for patients on long-term treatment. Excessive alcohol consumption should be avoided while taking this medication, as alcohol can increase the risk of side effects. Before and after surgical procedures or radiographic studies with contrast agents, this medication should be discontinued for a period of time, and it should only be resumed after confirming normal kidney function. In cases of overdose, immediate medical attention is required, and dialysis treatment may be beneficial if needed. Special caution is needed when administering this medication to children or the elderly, especially since elderly patients commonly have decreased kidney function, necessitating dosage adjustments and regular evaluations. This medication does not significantly impact driving or operating machinery, but caution is advised as dizziness can occur. Lastly, this medication should be stored out of reach of children and kept in its original container to prevent misuse or deterioration of quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • reduced fluid volume
  • thirst
Show 86 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • vitamin B12 deficiency
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burns
  • wrist fracture
  • gastrointestinal stromal tumor
  • malignant neoplasm of the lung
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • dental pain
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory abnormalities
  • drowsiness
  • tremors
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • chondromalacia
  • limb pain
  • periarticular inflammation
  • tendinosis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • itching
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to protect it from air and moisture. It is advisable to maintain a storage temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow, film-coated egg-shaped tablet with a biconvex surface on both sides

Package unit

30 tablets / bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.